| Background:Previous studies found that sinomenine can affect the release of inflammatory cytokines through the regulation of dendritic cells (DC) on TLRs,and the experimental animal models of arthritis joint pathological changes have improved. Rheumatoid arthritis (RA) is a multifactorial autoimmune disease, and the abnormal activation of T cells plays a very important role in the pathogenesis of RA. T cells recognize antigen presenting cells (APC) by TCR to present the antigen peptide-MHC molecular complex and are activated, the secretion of inflammatory cytokines activated macrophages, neutrophils. As a full time APC, the Stimulation and regulation of T cells is the main function of dendritic cells. Based on this, this paper further research study of sinomenine on DC maturation and cytokine, and to provide experimental basis for the treatment of rheumatoid arthritis.Objective:By in vitro induced by RA of murine bone marrow derived dendritic cells (BMDC) culture and observe the different growth stages of biological morphology and proliferation of lymphocytes stimulated with; to explore the different concentrations of sinomenine in vitro dendritic cells (DC) and to observe the changes of biological activity and surface of DC sign change in matter of CD80, CD86, CDllc and inflammatory factor IL-6, IL-12 and interferon gamma and sinomenine anti RA clinical application and provide experimental basis.Method:SPF bal/c mice, on the basis of literature was improved after establishment of collagen inducible model of rheumatoid arthritis (CIA), modeling after cervical dislocation, the mice were killed, according to literature improvement of bone marrow-derived DC culture,5th day with lipopolysaccharide (LPS) stimulate the maturation of DCS, on the sixth day using flow cytometry direct immunofluorescence on income cell detection CDllc, CD86 expression to identify dendritic cells (DC). Cultured mature DC cells were divided into blank group, model group, sinomenine high, and low dose group, MTX group. Each group was given different concentration sinomenine treatment for 24 hours, by flow cytometry of CD80, CD86, CDllc expression and cell culture supernatant was detected by ELISA, the expression level of IL-6, IL-12 and interferon gamma. The experimental data were analyzed by SPSS 19.0 software.Results:1 bovine type II collagen with Freund’s complete adjuvant to tail root, abdomen and foot pad injection on mice induced RA model in 35 days;2.IL-4 and GM-CSF can induce bone marrow stem cells into DC and DC in the training process is often in the state of the colony in fifth days;The expression of DC in the model group,3 CD80 on the surface of CD86 was significantly higher than the control group, the surface may affect DC cell costimulatory molecule RA modeling process (CD80, CD86) expression;4 sinomenine can downregulate expression of stem cell surface DC prognosis of CD80 and CD86, suggesting that it can inhibit DC cell maturation;5 sinomenine can reduce the secretion of DC cells, IL-6 IL-12, IFN-gamma and other inflammatory factors, reduce inflammation and immune response.Conclusion:Sinomenine by reduced DC cell surface CD80 and CD86 expression and inhibit the maturation, and the inhibition of antigen presentation and inhibit the secretion of inflammatory factors related to the dendritic cells and T cell activation, inhibition mediated immune response. To alleviate or prevent the RA chronic inflammation process, so that the destruction of the bone tissue and joint synovial tissue to be controlled in order to achieve the role of the treatment of RA. |
PDF Full Text Request